Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Rating of “Hold” from Analysts

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been assigned a consensus recommendation of “Hold” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $4.5333.

Several research firms have recently weighed in on ZNTL. Leerink Partners reaffirmed a “market perform” rating and set a $2.00 price objective on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th. Wall Street Zen raised Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Morgan Stanley cut their price objective on Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 12th. Wedbush restated a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research note on Wednesday, October 8th.

Zentalis Pharmaceuticals Stock Up 1.5%

NASDAQ:ZNTL opened at $1.37 on Friday. The company’s 50 day moving average is $1.39 and its 200-day moving average is $1.46. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $3.33. The firm has a market cap of $98.98 million, a price-to-earnings ratio of -0.66 and a beta of 1.75.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Monday, November 10th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.12. Research analysts predict that Zentalis Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Insider Activity at Zentalis Pharmaceuticals

In related news, major shareholder Matrix Capital Management Comp sold 7,500,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $1.33, for a total transaction of $9,975,000.00. Following the transaction, the insider owned 6,459,973 shares of the company’s stock, valued at $8,591,764.09. This trade represents a 53.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.90% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Invesco Ltd. raised its stake in shares of Zentalis Pharmaceuticals by 193.8% during the 1st quarter. Invesco Ltd. now owns 149,484 shares of the company’s stock worth $238,000 after purchasing an additional 98,612 shares in the last quarter. American Century Companies Inc. raised its position in Zentalis Pharmaceuticals by 46.2% during the first quarter. American Century Companies Inc. now owns 46,900 shares of the company’s stock worth $75,000 after acquiring an additional 14,816 shares in the last quarter. Ieq Capital LLC lifted its stake in Zentalis Pharmaceuticals by 521.4% in the first quarter. Ieq Capital LLC now owns 93,920 shares of the company’s stock valued at $149,000 after acquiring an additional 78,805 shares during the last quarter. State of Wyoming grew its position in shares of Zentalis Pharmaceuticals by 30.1% in the 1st quarter. State of Wyoming now owns 45,176 shares of the company’s stock valued at $72,000 after acquiring an additional 10,460 shares during the period. Finally, AQR Capital Management LLC increased its stake in shares of Zentalis Pharmaceuticals by 177.6% during the 1st quarter. AQR Capital Management LLC now owns 619,330 shares of the company’s stock worth $985,000 after purchasing an additional 396,233 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.